Who is sponsoring NCT06361823?

NCT06361823 is sponsored by Capital Medical University.

What drugs are being tested in NCT06361823?

Interventions in NCT06361823: Semaglutide, Low calorie diet.

What condition does NCT06361823 study?

NCT06361823 studies Idiopathic Intracranial Hypertension.

Is NCT06361823 still recruiting?

NCT06361823 is currently not yet recruiting. Last updated 12 April 2024.

Last reviewed 2024-04-12 · How we verify

NCT06361823

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

Not yet recruiting Phase 3 Last updated 12 April 2024

What this trial tests

Phase 3 trial testing Semaglutide in Idiopathic Intracranial Hypertension in 74 participants. Not yet recruiting.

Timeline

1 May 2024

Primary endpoint
1 December 2024

1 January 2025

Quick facts

Lead sponsor	Capital Medical University
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	74
Start date	1 May 2024
Primary completion	1 December 2024
Estimated completion	1 January 2025

Drugs / interventions tested

Semaglutide (semaglutide) — full drug profile →
Low calorie diet

Conditions studied

Idiopathic Intracranial Hypertension — all drugs for Idiopathic Intracranial Hypertension →

Sponsor

Capital Medical University

Who can join

Adults 18 to 75, any sex, with Idiopathic Intracranial Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the safety and efficacy of semaglutide in patients with Idiopathic intracranial hypertension.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.
Salvador R, Moutinho CG, Sousa C, Vinha AF, et al · · 2025 · cited 9× · PMID 40143174 · DOI 10.3390/ph18030399
Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.
Ognard J, Alipour Khabir S, Ghozy S, El Hajj G, et al · · 2025 · cited 1× · PMID 41057780 · DOI 10.1186/s10194-025-02148-3

Verify or expand the search:

Other trials of Semaglutide

Trials testing the same drug.

NCT07430332 — GLP-1 RA for Stage 1 Type 1 Diabetes · Phase 2 · not yet recruiting
NCT06977438 — Promoting Healthy Children and Youth · Phase 4 · not yet recruiting
NCT07218354 — Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial · Phase 3 · not yet recruiting
NCT07511543 — Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy · Phase 2 · not yet recruiting
NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting

Other recruiting trials for Idiopathic Intracranial Hypertension

Currently open trials in the same condition.

NCT06855342 — Prospective Ocular Imaging for Intracranial Pressure Evaluation · recruiting
NCT06545981 — Ocular Perfusion in Patients With Idiopathic Intracranial Hypertension · recruiting
NCT06059703 — Biomarkers in the Etiology of Idiopathic Intracranial Hypertension · NA · recruiting
NCT03556085 — Venous Sinus Stenting With the River Stent in IIH · NA · active not recruiting
NCT03096743 — Evaluating Raised Intracranial Pressure Using MR Elastography · NA · active not recruiting

Other Capital Medical University trials

Trials by the same sponsor.

NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06361823 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
Last refreshed: 12 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06361823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing